Welcome to ActoGeniX

ActoGeniX is a biopharmaceutical company, focused on the development and commercialization of a new generation of biological drugs; ActoBiotics™.

About ActoGeniX

ActoGeniX’s mission is to develop and commercialize innovative biological therapies, to improve the treatment and well-being of patients with gastrointestinal, immunological and metabolic diseases.


More about ActoGeniX →

About ActoBiotics™

ActoBiotics™ represent a novel concept for oral administration of therapeutic proteins, and are designed to be safer and more effective than injectable biopharmaceuticals. This novel class of biopharmaceuticals has the potential to treat a broad range of severe diseases.


More about ActoBiotics™ →

Video: What are ActoBiotics™?

Watch our introduction video on ActoBiotiocs by clicking on the image.


Recent Updates

Please click here for the latest news and headlines from ActoGeniX.

Show all news & events

ActoGeniX Announces Positive Results From a Phase 1 Study of AG014



ActoGeniX Announces Positive Results From a Phase 1 Study of AG014; Oral Capsule Administration of an Anti-TNF-Alpha Antibody for

Bacteria as a vehicle for drug delivery


WIPO | MAGAZINE August 2014

ActoGeniX, a small Belgian biotech company, is breaking new ground in developing a new class …

Jefferies 2014 Global Healthcare Conference


November 19-20, 2014
Waldorf Hilton, London